NewsDialy
Vertex Pharmaceuticals announced Monday it will acquire Crinetics Pharmaceuticals for $10 billion, or roughly $85 per share, adding a commercial rare-disease therapy and additional pipeline candidates to its portfolio.
The deal centers on Palsonify, a treatment for acromegaly that Crinetics launched last year. Crinetics shares jumped 101 percent in after-hours trading on the news.
What Acromegaly Is and Why a Commercial Drug Changes the Math Acromegaly is a rare endocrine disorder — meaning it stems from a malfunction in the body's hormone-regulating systems.
The condition affects a small number of patients, which is precisely what can make a dedicated treatment attractive to a large pharmaceutical company: rare diseases often carry limited competition, meaningful unmet need, and pricing power that broader-market drugs rarely see.
Keep reading